Cited by 1,213

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Ko, Myunggon, Huang, Yun, Jankowska, Anna M., Pape, Utz J., Tahiliani, Mamta, Bandukwala, Hozefa S., An, Jungeun, Lamperti, Edward D., Koh, Kian Peng, Ganetzky, Rebecca, Liu, X. Shirley, Aravind, L., Agarwal, Suneet, Maciejewski, Jaroslaw P., Rao, Anjana·2010·Nature

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature09586

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009) · DOI · Paper page
  2. Iyer, L. M., Tahiliani, M., Rao, A. & Aravind, L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8, 1698–1710 (2009) · DOI
  3. Viguié, F. et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19, 1411–1415 (2005) · DOI
  4. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009) · DOI · Paper page
  5. Jankowska, A. M. et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113, 6403–6410 (2009) · DOI · Paper page
  6. Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet. 41, 838–842 (2009) · DOI · Paper page
  7. Levine, R. L. & Carroll, M. A common genetic mechanism in malignant bone marrow diseases. N. Engl. J. Med. 360, 2355–2357 (2009) · DOI
  8. Mullighan, C. G. TET2 mutations in myelodysplasia and myeloid malignancies. Nature Genet. 41, 766–767 (2009) · DOI
  9. Tefferi, A. et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23, 900–904 (2009) · DOI
  10. Tefferi, A. et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23, 1343–1345 (2009) · DOI
  11. Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905–911 (2009) · DOI
  12. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010) · DOI · Paper page
  13. Hayatsu, H. & Shiragami, M. Reaction of bisulfite with the 5-hydroxymethyl group in pyrimidines and in phage DNAs. Biochemistry 18, 632–637 (1979) · DOI
  14. Huang, Y. et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 5, e8888 (2010) · DOI
  15. Tefferi, A. Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leuk. Lymphoma 49, 2231–2232 (2008) · DOI
  16. Smith, L. T., Otterson, G. A. & Plass, C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23, 449–456 (2007) · DOI
  17. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008) · DOI
  18. Gal-Yam, E. N., Saito, Y., Egger, G. & Jones, P. A. Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 59, 267–280 (2008) · DOI
  19. Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics 1, 239–259 (2009) · DOI
  20. Lengauer, C. Cancer. An unstable liaison. Science 300, 442–443 (2003) · DOI
  21. Bröske, A.-M. et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature Genet. 41, 1207–1215 (2009) · DOI · Paper page
  22. Jiang, Y. et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113, 1315–1325 (2009) · DOI · Paper page

Cited by

See all 1,213

Metadata

Authors
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., Liu, X. S., Aravind, L., Agarwal, S., Maciejewski, J. P., & Rao, A.
Venue
Nature
Published
2010-12
Volume
468
Issue
7325
Pages
839-843
ISSN
  • 0028-0836
  • 1476-4687
Cited by
1,213
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review